DETALLE RETO

---

Descripción

In humans, the Vanin 1 and 2 genes encode secreted and membrane-bound ectoenzymes that convert pantetheine into pantothenic acid and cysteamine. We share for collaboration a highly potent and selective dual Vanin inhibitor that blocks the enzymatic activity of Vanin 1 and 2, suitable for investigations in vitro and in vivo. Interested scientists are invited to submit testable research proposals that demonstrate utility of Vanin enzymatic activity inhibition in novel disease indications with high unmet medical need. BI-4122 is an orally available small molecule inhibitor that blocks in a reversible, competitive manner the enzymatic activity of Vanin 1 and 2, and therefore potently inhibits the conversion of pantetheine into pantothenic acid and cysteamine. Interested scientists are invited to submit testable research proposals that demonstrate utility of Vanin enzymatic activity inhibition in novel disease indications with high unmet medical need.

Incentivo

All incoming proposals will be evaluated by a scientific jury comprising of Boehringer Ingelheim scientists, and, upon selection, chosen proposals would be pursued through joint collaborations with the successful applicants. Funding of up to 200,000 euros will be available for each selected proposal

ODS

Salud y bienestar

Palabras clave

Medicina personalizada